Groupe Francophone Des Myelodysplasies
Clinical trials sponsored by Groupe Francophone Des Myelodysplasies, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a Centuries-Old poison become a new weapon against a blood disorder? Results expected Oct 2026 (estimated)
- New combo tackles relapsed blood cancers after transplant Results expected Nov 2026 (estimated)
- Can a Gene-Targeted pill turn the tide against a rare blood cancer? Results expected Apr 2027 (estimated)
-
Can a p53-Targeting drug boost chemotherapy in Hard-to-Treat blood cancers?
Disease control CompletedResearchers are testing a drug called APR-246 combined with azacitidine in people with myeloid blood cancers that carry a TP53 mutation, including myelodysplastic syndrome, acute myeloid leukemia, myeloproliferative neoplasms, and chronic myelomonocytic leukemia. The trial aims t…
Phase 1/2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can a new drug offer hope for blood cancers when chemo fails?
Disease control CompletedThis trial is testing an experimental drug called BST-236 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not improved after initial treatment. Participants receive BST-236 as a one-hour intravenous infusion for six …
Phase 2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Leukemia treatment showdown: which works best?
Knowledge-focused CompletedThis registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes…
Sponsor: Groupe Francophone des Myelodysplasies • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC